AAPL 184.35 1.1134% MSFT 411.6876 2.364% GOOG 145.3444 1.0459% GOOGL 144.175 1.14% AMZN 174.33 3.4047% NVDA 784.65 16.2927% META 486.18 3.878% TSLA 197.565 1.435% TSM 129.25 3.1195% LLY 769.655 3.1834% V 283.785 2.5383% AVGO 1304.8 6.3017% JPM 183.325 1.3405% UNH 525.425 0.6619% NVO 124.57 3.01% WMT 175.35 0.9499% LVMUY 182.36 1.7066% XOM 104.775 -0.0715% LVMHF 909.7617 1.9427% MA 471.85 2.7884%

Synlogic Inc

Healthcare US SYBX

1.94USD
-0.03(1.52%)

Last update at 2024-02-22T20:57:00Z

Day Range

1.942.16
LowHigh

52 Week Range

1.6116.50
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -66.14700M -60.56100M -59.17300M -51.37300M -48.43500M
Minority interest - - - - -
Net income -64.87500M -58.11800M -56.53700M -48.67100M -48.43500M
Selling general administrative 16.55M 15.39M 13.54M 14.73M 15.72M
Selling and marketing expenses - - - - -
Gross profit 1.18M 1.75M 0.55M 2.22M 2.52M
Reconciled depreciation 2.52M 2.44M 2.64M 2.70M 2.42M
Ebit -67.41900M -63.20800M -63.10200M -57.11100M -53.65100M
Ebitda -63.62500M -60.76500M -60.46600M -54.40900M -51.23000M
Depreciation and amortization 3.79M 2.44M 2.64M 2.70M 2.42M
Non operating income net other - 0.21M 1.30M 3.06M 2.84M
Operating income -67.41900M -60.76500M -60.46600M -54.40900M -51.23000M
Other operating expenses 68.60M 62.52M 61.01M 56.63M 53.75M
Interest expense 0.00200M 0.00200M 0.00600M 0.02M 0.04M
Tax provision - - - - -
Interest income 1.27M 0.21M 1.30M 3.06M 2.84M
Net interest income 1.26M 0.21M 1.30M 3.04M 2.80M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.27200M -2.44300M -2.63600M -2.70200M 2.84M
Total revenue 1.18M 1.75M 0.55M 2.22M 2.52M
Total operating expenses 68.60M 62.52M 61.01M 56.63M 53.75M
Cost of revenue - - - - 0.00000M
Total other income expense net 1.27M 0.20M 1.29M 3.04M 2.79M
Discontinued operations - - - - -
Net income from continuing ops -66.14700M -60.56100M -59.17300M -51.37300M -48.43500M
Net income applicable to common shares -66.14700M -60.56100M -59.17300M -51.37300M -48.43500M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 110.86M 174.74M 143.84M 188.57M 140.34M
Intangible assets - - 9.59M 16.38M -
Earning assets - - - - -
Other current assets 0.17M 0.31M 0.25M 0.65M 0.39M
Total liab 28.25M 27.47M 28.70M 31.67M 16.24M
Total stockholder equity 82.61M 147.27M 115.14M 156.91M 124.10M
Deferred long term liab - 9.31M 9.59M 16.38M 7.69M
Other current liab 5.29M 4.40M 3.77M 3.95M 5.43M
Common stock 0.07M 0.07M 0.04M 0.03M 0.03M
Capital stock 0.07M 0.07M 0.04M 0.03M 0.03M
Retained earnings -357.01900M -290.87200M -230.31100M -171.13800M -119.76500M
Other liab - - 0.13M - 7.69M
Good will - - - - -
Other assets 9.40M 10.41M 10.69M 17.54M 1.16M
Cash 15.86M 16.44M 32.51M 26.18M 11.25M
Cash and equivalents - - - - -
Total current liabilities 12.12M 10.08M 8.30M 8.86M 8.34M
Current deferred revenue 0.88M 0.53M - 0.54M 0.27M
Net debt 4.44M 4.16M -9.70100M -1.17000M -10.77600M
Short term debt 4.17M 3.20M 2.53M 2.21M 0.27M
Short long term debt - - - - -
Short long term debt total 20.30M 20.59M 22.81M 25.01M 0.48M
Other stockholder equity 439.72M 438.11M 345.39M 327.90M 243.90M
Property plant equipment 21.68M 9.09M 26.30M 30.28M 14.84M
Total current assets 79.78M 136.63M 100.44M 127.07M 122.73M
Long term investments 0.00000M 8.04M 0.00000M 7.50M -
Net tangible assets 82.61M 147.27M 115.14M 156.91M 124.10M
Short term investments 61.77M 112.15M 67.94M 93.39M 111.48M
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 1.78M 1.94M 2.00M 2.17M 2.38M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.16100M -0.04500M 0.01M 0.11M -0.06500M
Additional paid in capital - - - - -
Common stock total equity - 0.07M 0.04M 0.03M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - -290.87200M -230.31100M -171.13800M -119.76500M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 9.40M 20.98M 23.03M 48.48M 2.77M
Deferred long term asset charges - - - - -
Non current assets total 31.08M 38.11M 43.40M 61.50M 17.61M
Capital lease obligations 20.30M 20.59M 22.81M 25.01M 0.48M
Long term debt total - - - 0.00200M 0.21M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 58.35M -52.57400M 32.48M 12.05M -81.54700M
Change to liabilities 0.70M 0.41M -0.89300M -0.93500M -0.25700M
Total cashflows from investing activities 58.35M -53.25300M 32.48M 10.80M -87.20100M
Net borrowings -0.01300M 0.04M -0.20800M -0.26600M -0.42700M
Total cash from financing activities -2.04000M 89.38M 13.39M 79.60M 82.48M
Change to operating activities -0.32500M -0.86900M 12.26M -30.36000M 1.40M
Net income -66.14700M -60.56100M -59.17300M -51.37300M -48.43500M
Change in cash -0.57700M -16.06900M 6.32M 14.93M -47.18800M
Begin period cash flow 17.54M 33.60M 27.28M 12.35M 59.54M
End period cash flow 16.96M 17.54M 33.60M 27.28M 12.35M
Total cash from operating activities -56.88800M -52.19800M -39.55300M -75.46800M -42.47000M
Issuance of capital stock 0.29M 89.09M 13.54M 57.00M 82.67M
Depreciation 2.52M 2.44M 2.64M 2.70M 2.42M
Other cashflows from investing activities - - - 12.05M -81.54700M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock -2.51800M 81.04M 13.54M 79.87M 82.91M
Other cashflows from financing activities 0.20M 0.30M 0.06M 22.87M 0.24M
Change to netincome - 3.36M 5.62M 4.13M 4.33M
Capital expenditures 0.73M 0.68M 0.40M 1.25M 5.65M
Change receivables - - - - -
Cash flows other operating - 1.89M 13.32M -28.71400M 0.88M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -16.06900M 6.32M 14.93M -47.18800M
Change in working capital 0.72M 0.20M 11.36M -31.01900M 0.62M
Stock based compensation 3.64M 3.36M 3.91M 4.13M 4.32M
Other non cash items 2.38M 2.10M 1.74M 1.37M -1.39300M
Free cash flow -57.61600M -52.87700M -39.94800M -76.71900M -48.12400M

Fundamentals

  • Previous Close 1.97
  • Market Cap35.56M
  • Volume109695
  • P/E Ratio-
  • Dividend Yield0.0%
  • EBITDA-59.65500M
  • Revenue TTM0.71M
  • Revenue Per Share TTM0.15
  • Gross Profit TTM 1.18M
  • Diluted EPS TTM-12.68

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SYBX
Synlogic Inc
-0.03 1.52% 1.94 0.0 0.0 42.57 0.77 25.88 -0.32
NVO
Novo Nordisk A/S
3.64 3.01% 124.57 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
5.12 4.29% 124.40 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
7.83 1.87% 427.46 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd
1.03 1.11% 93.74 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

Profile

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Synlogic Inc

301 Binney Street, Cambridge, MA, United States, 02142

Key Executives

Name Title Year Born
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc Pres, CEO & Director 1976
Mr. Antoine Awad Chief Operating Officer 1980
Dr. Timothy K. Lu M.D., Ph.D. Co-Founder & Member of Scientific Advisory Board 1981
Dr. James J. Collins Ph.D. Co-Founder & Member of Scientific Advisory Board 1966
Mr. Michael Jensen Chief Financial Officer NA
Dr. David L. Hava Ph.D. Chief Scientific Officer 1975
Dr. Elizabeth Wolffe Head of Investor Relations & Corp. Communications NA
Mr. Brendan St. Amant Gen. Counsel & Corp. Sec. NA
Mr. Ajay Munshi VP of Corp. Devel. NA
Mr. Adam Thomas Chief People Officer NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).